Bortezomib Followed by Pembrolizumab and Cisplatin in metTNBC

NCT04265872 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Bortezomib; pembrolizumab and cisplatin injections--bortezomib followed by pembro/cis

Sponsor

Baylor Research Institute